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Background: Patients on chronic dialysis are at increased risk of vitamin D deficiency. In observational studies
plasma 25-hydroxyvitamin D (p-25(OH) D) levels are inversely correlated with plasma BNP and adverse cardiovascular
outcomes. Whether a causal relation exists has yet to be established. The aim of this study was to test the hypothesis
that cholecalciferol supplementation improves cardiac function and reduces blood pressure (BP) and pulse wave
velocity (PWV) in patients on chronic dialysis.
Methods: In a randomized, placebo-controlled, double-blind study, we investigated the effect of 75 μg (3000 IU)
cholecalciferol daily for 6 months, in patients on chronic dialysis. We performed two-dimensional echocardiography,
with doppler and tissue-doppler imaging, 24-h ambulatory BP (24-h BP), PWV, augmentation index (AIx), central BP
(cBP) and brain natriuretic peptide (BNP) measurements at baseline and after 6 months.
Results: Sixty-four patients were allocated to the study. Fifty dialysis patients with a mean age of 68 years (range:
46–88) and baseline p-25(OH) D of 28 (20;53) nmol/l completed the trial. Cholecalciferol increased left ventricular (LV)
volume, but had no impact on other parameters regarding LV structure or left atrial structure. LV systolic function, LV
diastolic function, PWV, cBP, AIx and BNP were not changed in placebo or cholecalciferol group at follow-up. 24-h BP
decreased significantly in placebo group and tended to decrease in cholecalciferol group without any difference
between treatments.
Conclusion: Six months of cholecalciferol treatment in patients on chronic dialysis did not improve 24-h BP, arterial
stiffness or cardiac function.
Trial registration: NCT01312714, Registration Date: March 9, 2011.
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Patients with CKD have profound reductions in plasma
levels of both 25-hydroxyvitamin D [25(OH) D] and the
more potent 1,25 dihydroxyvitamin D [1,25(OH)2D]
[1-4]. In patients with CKD, low 25(OH) D levels are as-
sociated with higher brain natriuretic peptide (BNP)
levels [5], increased cardiovascular events [6,7] and in-
creased mortality [8]. However, these observations are
prone to confounding, because healthier people may
spend more time outdoors.* Correspondence: frchri@rm.dk
1University Clinic in Nephrology and Hypertension, Department of Medical
Research and University of Aarhus, Holstebro Hospital, Holstebro, Denmark
2Department of Medicine, Holstebro Hospital, Laegaardvej 12, Holstebro
7500, Denmark
Full list of author information is available at the end of the article
© 2014 Mose et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The importance of vitamin D to mineral metabolism is
established but vitamin D may possess beneficial effects
on the cardiovascular system in patients with CKD. The
vitamin D receptors are widely expressed in human tis-
sues, and recent studies have also found active 1α-
hydroxylase in extra-renal tissues, in including cardiac tis-
sue [9] and vascular smooth muscle cells [10,11]. In
addition, extra-renal produced 1,25(OH)2D seems to have
important paracrine and autocrine effects [12,13], which
may be highly relevant in patients with reduced renal mass
and impaired renal 1,25(OH)2D production.
Active vitamin D analogue treatment is associated with
improved survival in dialysis patients [14], and in spon-
taneously hypertensive rats active Vitamin D analogues
prevented left ventricular hypertrophy [15]. In dialysistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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predictor of all-cause mortality [16] and cholecalciferol
supplementation was associated with reduced p-BNP
and reduced left ventricular mass (LVM) [3,17].
Randomized controlled trials establishing the effect of
cholecalciferol supplementation on cardiac function and BP
in patients with CKD are still mandated. The aim of this
study was to test the hypothesis that cholecalciferol supple-
mentation improves cardiac function and reduces BNP,
24 hour ambulatory BP (24-h BP) and pulse wave velocity
(PWV) in patients with stage 5 CKD on chronic dialysis.
Methods
Study population
Subjects passed a screening examination that included med-
ical history and physical examination. Inclusion criteria:
Both men and women, age above 18 years, dialysis treat-
ment for more than 3 months. Exclusion criteria: Current
malignant disease, hypercalcemia (albumin corrected serum
calcium> 2.60 mmol/L), allergy or intolerance towards cho-
lecalciferol tablets, incapability to give informed consent.
Withdrawal criteria: Renal transplantation, non-compliance,
clinical complications rendering oral ingestion of tablets or
trial completion impossible, transferral to another dialysis
department and withdrawal of informed consent.
Design
The study was a single-center, randomized, placebo-
controlled, double blinded, trial. After inclusion subjects
were allocated to treatment via computer-generated
randomization in blocks of ten and received 3000 IU
(75 μg) cholecalciferol daily or placebo for 6 months.
Study drugs
Cholecalciferol and placebo were identical in appearance
and were given orally and were obtained from Ferrosan
A/S, Soeborg, Denmark.
Ethics
The study was approved by the Regional Committee on
Biomedical Research Ethics, and carried out in accord-
ance with the Declaration of Helsinki. Written, informed
consent was obtained from each subject.
Effect variables
The main effect variable was p-BNP. Other effect variables
were 24-h BP, central diastolic BP (cDBP), central systolic
BP (cSBP), PWV, AIx and plasma concentrations of renin
(PRC), angiontensin II (p-AngII), aldosterone (p-Aldo), 25
(OH) D, intact parathyroid hormone (p-PTH), ionized cal-
cium (p-Ca2+), phosphate (p-phosphate), alkaline phosphat-
ase and C-reactive protein (p-CRP). In echocardiography,
structural parameters included left ventricular mass index
(LVMI), Left ventricular (LV) wall thickness and LVdiastolic volume and diameter and functional parameters.
Functional parameters included LV Ejection Fraction, LV
longitudinal function assessed by tissue Doppler, LV global
and local strain assessed by 2D Speckle Tracking, and LV
diastolic function assessed by early mitral inflow wave vel-
ocity/early diastolic mitral annular velocity ratio (E/e’),
early/late mitral inflow wave velocity ratio (E/A) and
E-wave deceleration time.
Recruitment
Patients were consecutively recruited from the Dialysis
Department and Outpatients’ Clinic of Renal Diseases,
Holstebro Hospital All patients in our dialysis depart-
ment were screened for participation.
Number of subjects
With a significance level of 5% and a power of 80% a
total of 56 subjects (28 in each group) were needed to
detect a 15 pmol/l difference in p-BNP (SD 20 pmol/l).
The aim was to include 80 patients due to an expected
withdrawal of 25%. The power calculation was based on
previous observational data of cholecalciferol supple-
mentation in hemodialysis patients) [3].
Experimental procedure
Vitamin D supplementation of more than 10 μg of ergo- or
cholecalciferol daily was paused 3 months prior to alloca-
tion treatment group and baseline measurements. Trans-
thoracic echocardiography (TTE), applanation tonometry
and 24-h BP was performed at baseline and repeated after
6 months of treatment. Measurements were performed on
the same day. After arrival at the research facility, TTE was
performed followed by applanation tonometry and venous
blood sampling for evaluation of vasoactive hormones
(PRC, p-Ang II, p-Aldo, p-AVP and p-BNP). In peritoneal
dialysis (PD) patients 24-h BP equipment was mounted
after blood sampling. In hemodialysis (HD) patients a regu-
lar dialysis was performed after TTE, applanation tonome-
try and blood sampling, and 24-h BP equipment was
mounted after the dialysis session had finished. In HD pa-
tients, baseline and follow-up measurements were per-
formed on a dialysis day, with an interdialytic interval as
short as possible prior to the measurements. Measure-
ments in PD patients were performed in relation to a visit
at the outpatient clinic. At the day of baseline and follow-
up examinations participants took their usual medication,
and were not allowed any alcoholic or caffeinated bever-
ages. At baseline and every 4 weeks blood samples were
obtained for assessment of plasma concentrations Ca2+,
phosphate, PTH and p-25(OH) D.
BP measurements
24-h BP was measured using Kivex TM-2430 (Kivex,
Hoersholm, Denmark). Equipment was mounted after
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every 15 minute during daytime and every 30 minute over
night. Brachial blood pressure used for calibration of Sphyg-
mocor system was measure as duplicate recording with
Omron 705IT (Omron Matsusaka CO. Ltd., Matsusaka
City, Japan). If measurements of the duplicate recording
exceeded 7 mmHg, the BP measurement was repeated.
TTE measurements
TTE was performed using a Vivid 7 (GE Medical Sys-
tems Inc., Horten, Norway) cardiac ultrasound system.
All images were stored for offline analysis. All measures
was performed separately, randomly, and blinded to
treatment allocation.
Left ventricular (LV) dimensions were obtained from
the parasternal long-axis view, with measurement of
end-diastolic interventricular septal thickness, LV pos-
terior wall thickness, and LV end-diastolic diameter just
below the tips of the anterior mitral leaflet. LV mass was
calculated using the Devereux formula and indexed to
body surface area to obtain the LV mass index (LVMI)
[18]. LV ejection fraction (LVEF) and LV volumes were
calculated from conventional apical two- and four-
chamber images, using the biplane Simpson technique.
Left atrial (LA) volume was assessed by the biplane
area-length method from apical 4- and 2-chamber views
at end systole from the frame preceding mitral valve
opening. Left atrial volume index was calculated as LA
volume to body surface area (mL/m2). Mitral inflow was
assessed in the apical 4-chamber view with the pulsed
wave Doppler sample volume placed at the tips of mitral
leaflets during diastole. From the inflow, peak E wave
velocity, E wave deceleration time and peak A wave were
measured. Mitral annular motion was assessed using
pulsed wave tissue Doppler with the sample volume
placed in the septal and lateral mitral annulus. The mean
of the septal and lateral e’ velocity was used for calcula-
tion of E/e’. Global and regional strain was measured by
2D speckle tracking. All measurements were estimated
as averages of three (sinus rhythm) or five (atrial fibrilla-
tion) consecutive heart beats.
Applanation tonometry
After echocardiography, subjects were transferred to the
dialysis department and supine position was assumed in
a quiet temperature controlled room (temperature range
21–24°C). After 30 minutes supine position, applanation
tonometry was performed. Recordings of pulse wave
analysis (PWA) and carotid-femoral PWV were obtained
by applanation tonometry (SphygmoCor® CPV system®,
AtCor Medical, Sydney, Australia) as double-recordings
by a trained observer. Only duplicate recording meet-
ing the quality requirements were included in the final
analysis [19].Biochemical analyses
Routine blood samples obtained at baseline and every
month through out the study were immediately assayed
at the Department of Clinical Biochemistry. Commer-
cial chemiluminescence immunoassays were used to
analyze plasma concentrations of 25(OH) D2 + 25(OH)
D3 (Liaison, DiaSorin, Saluggia, Italy) and BNP (Centaur,
Bayer Germany).
Blood samples for measurements of vasoactive hor-
mones were centrifuged for 10 minutes at 2200 G and 4°C.
Plasma was separated from blood cells and kept frozen
until assayed. PRC was determined using an immunoradio-
metric assay from CIS Bio International, Gif-Sur-Yvette
Cedex, France. Minimal detection level was 1 pg/ml. The
coefficients of variation were 0.9-3.6% (intra-assay) and
3.7-5.0% (inter-assay) in the range of 4–263 pg/ml. Aldo
was determined by RIA using a kit from Demeditec Diag-
nostics GmbH, Kiel, Germany. Minimal detection level
was 25 pmol/l. The coefficients of variation were 9.0% (in-
ter-assay) and 8.5% (intra-assay). Ang II were extracted
from plasma with C18 Sep-Pak (Water associates, Milford,
MA, USA), and subsequently determined by radioimmu-
noassay [20,21]. The antibody against Ang II was obtained
from the Department of Clinical Physiology, Glostrup Hos-
pital, Denmark. Minimal detection level was 2 pmol/L.
The coefficients of variation were 12% (inter-assay) and 8%
(intra-assay).
Statistics
Data are presented as means ± standard deviations
(±SD), if they showed normality, and as medians with
25% and 75% percentiles in brackets, if normality was
not found. Comparisons between groups were per-
formed with unpaired t-test or Mann–Whitney U-test.
Paired comparisons within groups were performed with
paired t-test or Wilcoxon signed rank test. Pearson’s cor-
relation was used to test for significant correlation be-
tween changes in p-BNP and changes in p-25(OH) D.
Statistical significance was defined as p < 0.05. Statistical
analyses were performed using PASW version 20.0.0
(SPSS Inc.; Chicago, IL, USA).
Results
Demographics
A total of 140 dialysis patients were screened for participa-
tion and 64 patients were included in the trial (Figure 1),
and had baseline measurements performed. During the
trial 14 patients were with-drawn due to kidney trans-
plantation (3), cerebrovascular disease which made oral
ingestion of tablets impossible (3), non-compliance (1),
withdrawal of consent (6) or hypercalcemia (1). Thus fol-
low up measurements were performed in 50 patients. Six
patients developed hypercalcemia, which was treated
within the guidelines of our department. Five of the
Assessed for eligibility 
(n=140, HD 114, PD 26) 
Did not meet inclusion criteria or not 
interested (n=76)
Randomized
(n=64, HD 53, PD 11)


















Figure 1 Flow chart.
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the cholecalciferol group. The patient in the cholecalcif-
erol group was the patient who was excluded due to per-
sistent hypercalcemia.
Baseline characteristics are shown in Table 1. Baseline
p-BNP and p-25(OH) D was similar between groups. At
baseline, p-25(OH) D was <80 nmol/L in 47 patients (86%),
and <50 nmol/L in 33 patients (66%). Mean compliance by
pill count was 99% in both groups.
Vasoactive hormones and calcium metabolism
Changes in p-BNP, PRC, p-Ang II and p-Aldo are given in
Table 2. Median changes in p-BNP, p-Ang II, PRC and p-
Aldo between baseline and follow-up did not differ at
follow-up or were significantly different between groups.
Changes in plasma levels of 25(OH) D, PTH, phosphate
and Ca2+ levels are depicted in Figure 2 with baseline and
follow-up values given in Table 2. There was no correl-
ation between changes in p-BNP and changes p-25(OH)
D from baseline to follow-up (r = −0.069, p = 0.633)
24-h BP and arterial stiffness
No difference in baseline 24-h BP was observed between
groups (Table 3). In placebo group 24-h SBP decreased
significantly (−9 ± 17 mmHg, p = 0.023) and 24-h DBP in-
significantly (−4 ± 10 mmHg, p = 0.068). In cholecalciferol
group 24-h SBP and 24-h DBP decreased tended todecrease (−5 ± 24, p = 0.376 and −2 ± 10 mmHg resp., p =
0.396). The reductions in 24-h BP were not different be-
tween groups. The same pattern was seen for day-time
and night-time values with no difference between groups.
cBP and measures of arterial stiffness are documented
in Table 4. Data on PWA and PWV were available on 41
and 40 patients, resp. No change between and within
groups was found in cBP and PWV. AIx decreased sig-
nificantly in placebo group and was unchanged in chole-
calciferol group, and the response was significantly
different between groups.
Echocardiography
Transthoracic echocardiography measures at baseline
and 6 months follow-up are shown in Table 5.
LV end diastolic volume increased significantly in the
cholecalciferol group compared to placebo. Cholecalciferol
treatment had no effect on LVEF, LVMI, LAVI, E wave de-
celeration time, E/A ratio or E/e’. Furthermore cholecalcif-
erol treatment had no impact on mitral plane systolic
motion, global or regional strain (data not shown).
Medication
Changes in calcium supplements, alfacalcidol, paricalci-
tol, calcimimitecs, phosphate binders and erythropoietin
analogues from baseline to follow-up are shown in
Table 6. Median changes were 0 for all the drugs in
Table 1 Baseline characteristics according to
randomization in a randomized, placebo-controlled,
double-blinded study of 50 dialysis patients
Placebo Vitamin-D3 P value
Age (years) 67 ± 13 68 ± 9 0.794
Body mass index (kg/m2) 23.8 ± 4.4 24.0 ± 4.5 0.856
Male sex, n (%) 15 (60) 17 (68) 0.556
Smokers, n (%)
Current 5 (20) 1(4) 0.220
Former 5 (20) 6 (24)
Never 15 (60) 18 (72)
Type 1 diabetes, n (%) 4 (16) 2 (8) 0.384
Type 2 diabetes, n (%) 5 (20) 2 (8) 0.221
HD, n (%)A 24 (96) 19 (76) 0.042
Dialysis sessions pr. week
for HD patients
3.2 ± 0.6 3.2 ± 0.6 0.817
Medication, n (%)
ACEi/ARBs 17 (68) 17 (68) 0.914
Calcium channel blockers 7 (28) 13 (54) 0.083
Beta blockers 11 (44) 15 (60) 0.285
Loop diuretics 11 (44) 12 (40) 0.777
Minoxidil 5 (20) 6 (24) 0.733
Alfa-blockers 2 (8) 1 (4) 0.552
Alfacalcidol 12 (48) 15 (60) 0.393
Paricalcitol 1 (4) 1 (4) 1.000
Cinecalcet 2 (8) 2 (8) 1.000
Phosphate binder 17 (68) 20 (80) 0.333
Lanthanum 3 (12) 4 (16) 0.684
Sevelamer 10 (40) 14 (56) 0.258
Calcium-containingB 15 (60) 17 (68) 0.254
Erythropoetin analogue 24 (96) 21 (84) 0.157
P-BNP (pmol/L) 81 (24;186) 61 (26;378) 0.600
P-25(OH) D (nmol/L) 28 (20;69) 28 (20;48) 0.614
Values are mean ± SD, n with percentage in brackets or medians with 25 and
75 percentiles in brackets. ACEi: Angiotensin converting enzyme inhibitors,
ARB: Angiotensin receptor blocker. BNP: Brain natriuretic peptide, 25(OH):
25-hydroxy-vitamin D AOne subject changed from peritoneal dialysis to
haemodialysis (HD) after two months and was placed in HD. BUnikalk or Osvaren.
Table 2 Effect of cholecalciferol (Vitamin D3) treatment
on calcium metabolism and vasoactive hormones in a
randomized, placebo-controlled study of 50 patients on
dialysis




Placebo 28 (20;69) 30 (22;50)
<0.001
Cholecalciferol 28 (20;48) 84 (65;125)*
P-PTH (pmol/L)
Placebo 18.0 (5.9;30.5) 12.9 (8.7;33.7)
0.986
Cholecalciferol 13.5 (5.8;29.6) 17.4 (9.1;35.3)
P-Ca2+ (mg/dL)
Placebo 1.20 ± 0.08 1.20 ± 0.07
0.724
Cholecalciferol 1.21 ± 0.11 1.20 ± 0.09
P-Phosphate (nmol/L)
Placebo 1.66 ± 0.37 1.59 ± 0.38
0.103
Cholecalciferol 1.59 ± 0.40 1.73 ± 0.47
P-Alkaline Phosphatase (U/L)
Placebo 67 (51;99) 72 (59;93)
0.393
Cholecalciferol 70 (48;92) 73 (48;106)
P-CRP (mg/L)
Placebo 4.5 (1.7;11.7) 2.5 (1.6;13.9)
0.237
Cholecalciferol 3.4 (1.1;13.3) 3.9 (1.1;11.3)
P-leukocytes (109/L)
Placebo 6.3 (5.2;7.7) 6.3 (5.6;7.3)
0.740
Cholecalciferol 6.3 (5.1;7.5) 5.8 (5.2;8.1)
P-Haemoglobin (mmol/L)
Placebo 7.3 ± 0.8 7,3 ± 0.7
0. 419
Cholecalciferol 7.4 ± 0.8 7.2 ± 0.6
P-BNP (pmol/L)
Placebo 81 (24;186) 50 (30;265)
0.820
Cholecalciferol 61 (26;378) 95 (35;363)
PRC (pg/mL)
Placebo 10 (4;19) 8 (6;23)
0.883
Cholecalciferol 6 (4;12) 8 (4;20)
P-Ang II (pg/mL)
Placebo 12 (7;23) 15 (4;33)
0.167
Cholecalciferol 7 (3;26) 12 (5;60)
P-Aldosterone (pmol/L)
Placebo 135 (49;300) 209 (68;329)
0.415
Cholecalciferol 125 (61;250) 155 (76;312)
Values are mean ± SD or medians with 25 and 75 percentiles in brackets.
25(OH): 25-hydroxy-vitamin D, PTH: parathyroid hormone, CRP, C-reactive
protein, BNP: Brain natriuretic peptide, PRC: Plasma renin concentration, Ang II:
Angiotensin II, P values represent the probability of a difference in response to
treatment between groups. Statistical significant difference from
baseline: * = p < 0.001.
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was continued throughout the study period in a majority
of the patients. There was no difference in mean dose
change for any of the drugs between groups.
The Number of patients, who had changes in antihyper-
tensive medication, is shown in Table 7. Median changes
were 0 for every antihypertensive drug. In placebo group,
33 dose-increases and 16 had dose-reductions were ob-
served, and in cholecalciferol group and in cholecalciferol
group 29 dose-increases and 23 dose-reductions were
observed.
Figure 2 Mean plasma concentrations of 25-hydroxy-vitamin D (p-25(OH)-D) (A), p-PTH (B), plasma ionised calcium (p-Ca2+) (C) and
p-phosphate (D) with SEM (n = 50).
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This is the first randomized, placebo-controlled, double-
blinded, single-centre intervention study investigating
the effects of cholecalciferol supplementation on cardiac
function in dialysis patients. Previous intervention stud-
ies, which found indication that cholecalciferol treat-
ment may reduce LVMI and BNP in patients on chronic
dialysis, were prospective uncontrolled studies [3,17].
We hypothesized that daily cholecalciferol supplementa-
tion in dialysis patients improves cardiac function and
reduces 24-h BP and arterial stiffness. Cholecalciferol
caused a marked increase in p-25(OH) D without in-
creased incidence of hypercalcemia or other adverse ef-
fects. After six months, no significant differences were
observed in p-BNP, cardiac function, 24-h BP or arterial
stiffness between groups.
Previously, intra-venous 1,25(OH)2D (calcitriol) reduced
LV hypertrophy in patients on hemodialysis with elevated
p-PTH [22,23]. Two prospective studies have demon-
strated a reduction in LVMI and p-BNP after 6 months of
cholecalciferol supplementation [3,17], which is in contrast
to our findings where no change was found. In this study
3,000 IU were given daily. Buchales and colleagues admin-
istered a higher (x 1.5) dose and Mathias and colleagues
used a substantial higher dose (x 2.4) in HD patients with
p-25(OH) D < 37 nmol/L but a lower dose (x 0.4 – 0.5) in
patients with p-25(OH) D > 37 nmol/L, than we used inthis study [3,17]. As in the previous studies, we found an
increased in p-25(OH) D levels in response to cholecalcif-
erol supplementation. Dialysis patients have reduced renal
mass and reduced renal 1α-hydroxylase activity [24], and
although cholecalciferol supplementation increased p-1,25
(OH)2D in patients on dialysis, the increase is impaired
compared to non-dialysis populations [1,3,25,26]. Vitamin
D receptors and 1α-hydroxylase is present in cardiac tissue
[9,27], but the increase in p-1,25(OH) D may not be suffi-
cient to activate the vitamin D receptor in cardiac tissue,
with the doses used in this study. However, antihyperten-
sive medication was changed during the study, which could
conceal the effects of cholecalciferol.
We found an increase in LV end-diastolic volume after
6 months of cholecalciferol treatment compared to pla-
cebo. This is not a beneficial effect, but the difference is
small and there were no differences with-in groups from
baseline to follow-up in LV end-diastolic volume. This
could be by chance and further studies will have to clar-
ify this.
Studies evaluating the effect of cholecalciferol on BP
have shown mixed results [28-30]. Two recent trials in
hypertensive patients measured BP as 24-h BP, and
could not demonstrate reductions in BP by cholecalcif-
erol supplementation [31,32], but a sub-group analysis
of 25(OH) D deficient patients showed a small but sig-
nificant reduction in 24-h BP [31]. We found a tendency
Table 3 Effect of 6 months cholecalciferol treatment
24 hour blood pressure (24-h BP) in a randomized,
placebo-controlled study of 50 patients on dialysis




Placebo 136 ± 22 127 ± 23†
0.511
Cholecalciferol 135 ± 18 130 ± 14
24-h DBP (mmHg)
Placebo 73 ± 10 69 ± 10
0.451
Cholecalciferol 73 ± 9 71 ± 8
24-h heart rate (bpm)
Placeb 74 ± 8 74 ± 7
0.464
Cholecalciferol 70 ± 9 71 ± 8
24-h daytime SBP (mmHg)
Placebo 138 ± 22 130 ± 22†
0.504
Cholecalciferol 137 ± 18 133 ± 15
24-h daytime DBP (mmHg)
Placebo 75 ± 11 71 ± 11
0.519
Cholecalciferol 74 ± 9 72 ± 8
24-h daytime heart rate (bpm)
Placebo 75 ± 8 76 ± 8
0.586
Cholecalciferol 71 ± 9 73 ± 9
24-h nighttime SBP (mmHg)
Placebo 131 ± 26 121 ± 27†
0.498
Cholecalciferol 129 ± 19 125 ± 17
24-h nighttime DBP (mmHg)
Placebo 69 ± 11 65 ± 11†
0.361
Cholecalciferol 69 ± 9 68 ± 11
24-h nighttime heart rate (bpm)
Placebo 70 ± 8 70 ± ± 6
0.270
Cholecalciferol 67 ± 9 69 ± ± 9
Values are means ± SD. P values represent the probability of a difference in
response to treatment between groups. Statistics are performed with t-test.
Statistical significant difference from baseline compared with paired t-test.
Statistical significant difference from baseline: † = p < 0.05.
Table 4 Effect of 6 months cholecalciferol treatment on
pulse wave velocity (PWV), augmentation index (AIx),
and central diastolic and systolic blood pressure (cDBP,
cSBP) in a randomized, placebo-controlled study of 50
patients on dialysis




Placebo (n = 19) 10.0 ± 2.0 10.1 ± 2.5
0.269
Cholecalciferol (n = 22) 9.7 ± 2.5 10.5 ± 4.0
AIx (%)
Placebo (n = 22) 26.4 ± 11.5 22.2 ± 11.2†
0.013
Cholecalciferol (n = 18) 22.1 ± 9.7 24.6 ± 12.7
cSBP (mmHg)
Placebo (n = 22) 127 ± 24 126 ± 26
0.744
Cholecalciferol (n = 18) 128 ± 14 125 ± 17
cDBP (mmHg)
Placebo (n = 22) 68 ± 11 70 ± 11
0.779
Cholecalciferol (n = 18) 71 ± 9 71 ± 12
Values are means ± SD or medians with 25 and 75 percentiles in brackets.
Statistics are performed with t-test. P values represent the probability of a dif-
ference in response to treatment between groups: Significant difference from
baseline: † = p < 0.05.
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but surprisingly an even larger and significant reduction
in BP in the placebo group. Blood pressure medication
was recorded at baseline and follow-up. In the placebo
group, 33 dose-increases and 16 dose-reductions (differ-
ence of 17) were recorded and in cholecalciferol group
29 dose-increases and 23 dose-reductions (difference of
6) were observed. There seems to be a majority of dose-
increases in the placebo group, which might explain the
reduction in BP seen in placebo group. In hemodialysis
patients BP is shown to increase in the inter-dialysis
period [33]. Since BP is dependent on volume status, an
improvement of volemic state might explain the reductionin BP. Hence, changes in 24-h BP are likely related to
changes in medication and volume status. Our results do
not suggest a benefit of cholecalciferol supplementation
on 24-BP, but BP reductions may induced by cholecalcif-
erol may be concealed by changes in volume status and
medication. Thus, we can not exclude that cholecalciferol
might have beneficial effects on BP.
PWV is a predictor for all-cause and cardiovascular
mortality in patients with end-stage renal disease [34]
and we found no change in PWV in the groups at
follow-up, which is in agreement with previous reports
[1,35]. PWV tends to increase in the inter-dialysis period
[36], most likely due to volume expansion. Hemodialysis
patients had PWV measurements performed just prior
to a dialysis session where volume-expansion is at its
highest and this could conceal effects of cholecalciferol
treatment. AIx decreased significantly in placebo group
and was unchanged in cholecalciferol group. Most likely
this is explained by the lower 24-h BP in the placebo
group. Previously cholecalciferol supplementation did
not change AIx [1], and this needs further clarification.
Vitamin D may play an important role in the modula-
tion of renin-angiotensin system in patients on dialysis. In
vitamin D receptor knock-out mice renin expression is
highly increased leading to hypertension and LV hyper-
trophy [37] and in mice active vitamin D analogue treat-
ment suppresses renin expression, independent of PTH
[38]. In dialysis patients, high dose intravenous vitamin D
analogue treatment led to a significant reduction in PRC
Table 5 Effect of six months cholecalciferol treatment on cardiac structure and function measured by transthoracic
echocardiography in a randomized, placebo-controlled study of patients on dialysis
Baseline 6 months P value (difference in response)
Left ventricular end-diastolic volume (biplane), ml
Placebo (n = 24) 109 ± 38 101 ± 43
0.024
Cholecalciferol (n = 22) 99 ± 33 108 ± 42
Left ventricular ejection fraction (biplane), %
Placebo 52 ± 14 52 ± 17
0.515
Cholecalciferol 53 ± 14 56 ± 12
Left ventricular mass index, g/m2
Placebo 116 ± 36 111 ± 39
0.397
Cholecalciferol 123 ± 34 127 ± 50
Left atrial volume index, ml/m2
Placebo 35 ± 14 37 ± 14
0.637
Cholecalciferol 40 ± 16 41 ± 14
Early/late mitral inflow wave velocity ratio (E/A)
Placebo 0.84 ± 0.21 0.89 ± 0.28
0.501
Cholecalciferol 1.10 ± 0.59 1.21 ± 0.72
Transmitral E-wave deceleration time, s
Placebo 228 ± 92 230 ± 76
0.455
Cholecalciferol 226 ± 62 215 ± 61
Early mitral inflow wave velocity/early diastolic mitral annular velocity ratio (E/e’)
Placebo 12 ± 6 13 ± 5
0.078
Cholecalciferol 15 ± 8 17 ± 9
Values are means ± SD. P values represent the probability of a difference in response to treatment between groups. Data was available for 24 patients in
cholecalciferol group and 22 patients in the placebo group. Statistics are performed with t-test. Statistical significant difference from baseline compared with
paired t-test.
Table 6 Changes in calcium supplements, alfacalcidol, paricalcitol, calcimimitecs, phosphate binders and erythropoietin
analogues in a randomized, placebo-controlled study investigating the effects of cholecalciferol supplementation for
6 months in 50 patients on dialysis
Vitamin D analogues Calcimimetic Phospahte binders Erythropoietin
analogues
Alfacalcidol Paricalcitol Cinecalcet UnikalkA Sevelamer Lanthanum OsvarenB Epoetin Darbapeotin
Placebo (changes
from baseline)
Increased dose (n) 7 0 1 0 6 1 7 1 7
Same dose (n) 10 25 23 22 13 23 12 23 6
Reduced dose (n) 8 0 1 3 6 1 6 1 12




















Increased dose (n) 8 1 1 2 3 3 3 0 9
Same dose (n) 12 23 22 17 14 18 17 25 6
Reduced dose (n) 5 1 2 6 8 4 5 0 10


















Mean change in dose is shown as mean ± SD AOne tablet contains 1000 mg calcium acetate BOne tablet contains 435 mg calcium acetate and 235 mg
magnesium carbonate.
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Table 7 Changes in antihypertensive mediation in a randomized, placebo-controlled study investigating the effects of
cholecalciferol supplementation for 6 months in 50 patients on dialysis










Increased dose (n) 6 4 4 9 6 4 0 0
Same dose (n) 18 19 19 14 15 16 25 25
Reduced dose (n) 1 2 2 2 4 5 0 0
Cholecalciferol
Increased dose (n) 3 5 3 4 7 4 2 1
Same dose (n) 16 19 18 18 14 18 23 22
Reduced dose (n) 6 1 4 3 4 3 0 2
ACE: Angiotensin converting enzyme, AT2: Angiotensin 2. A1 patient in placebo and 1 patient in cholecalciferol group had metroprolol substituted with carvedilol
in equivalent doses and is reported as given same dose beta-blocker.
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changed after active vitamin D analogue supplementation
in patients with CKD stage III-IV [39] and type 2 diabetics
with nephropathy [40] and after 6 months oral cholecalcif-
erol supplementation in hypertensives [31]. This is in
agreement with the finding in the present trial. Although
we recorded no effect of cholecalciferol on circulating
concentrations, these measurements might not be accur-
ate indicators of renin or angiotensin II activity within the
kidney in response to cholecalciferol. In addition, given
that patients were non-fasting and 68% were on angioten-
sin II receptor blocker or angiotensin-converting enzyme
inhibitor, conclusions regarding changes in the RAS
should be made with caution.
Previous conclusions from clinical trials regarding the
effect of vitamin D supplementation on PTH in dialysis
patients are inconsistent, with both suppressed [3,41,42]
and unchanged PTH [1,35,43-45] observed. In this
study, cholecalciferol plasma concentrations of calcium,
phosphate and PTH were unchanged. However, in this
trial setting the effect of cholecalciferol treatment is very
difficult to estimate. Cholecalciferol was used on top of
usual treatment and changes in p-calcium, p-phosphate
and PTH during the trial were regulated tightly with-in
the usual guidelines of our department. Although
medication changes regarding calcium and phosphate
metabolism in the 6 month treatment period were
small and did not seem different between groups, po-
tential changes in plasma concentrations of phos-
phate, calcium and PTH are most likely concealed by
medication changes.
Oral supplementation of 3,000 IU cholecalciferol daily
was highly effective in restoring p-25(OH) D levels with-
out increasing the risk of hypercalcemia or other adverse
effects. The incidence of persistent hypercalcemia, was
after the trial was finished associated with malignant dis-
ease, and was most likely not related to cholecalciferol
supplementation.The design as a randomised, placebo-controlled, double-
blinded, single-centre trial was an essential strength of the
present study. Compliance to study medication, docu-
mented by pill count, was high and a relatively high chole-
calciferol was given.
Usual dialysis and medical treatment, except nutri-
tional vitamin D supplementation, was continued during
study period, and adjusted as clinically warranted during
the course of the trial. We did not find it ethically justi-
fied to discontinue usual medication or with-hold opti-
mal treatment. Thus, the study was performed under
optimal care, and this may influence effect variables and
conceal the effects of cholecalciferol treatment. Patients
were included regardless of their p-25(OH) D levels.
Thus, some patients were had sufficient vitamin D levels.
In patients with sufficient vitamin D levels, raising vitamin
D levels further may not change outcomes, and this could
conceal potential beneficial effects of cholecalciferol sup-
plementation in vitamin deficient patients. Further investi-
gations in vitamin D deficient dialysis patients are needed
the address this problem.
We have not performed sub-group analysis since this
study was not powered for such analysis. For instance, both
patients on HD and PD were included in this study, but the
study was not powered to reveal a difference in response to
cholecalciferol between the different dialysis modalities.
Hence, it cannot be excluded that certain sub-groups might
benefit from cholecalciferol supplementation.
This study was powered to detect a difference in p-
BNP. For some of the secondary effect variables this
study may not have sufficient power to detect a differ-
ence. We cannot exclude that a bigger sample size could
reveal differences in some of the secondary effect
variables.
Conclusions
In conclusion, six months of cholecalciferol treatment in
patients on chronic dialysis did not improve 24-h BP,
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http://www.biomedcentral.com/1471-2369/15/50arterial stiffness or cardiac function. The study popula-
tion was a heterogeneous group of patients on dialysis
on usual medication, and although we did not find bene-
ficial effects of cholecalciferol supplementation, certain
subgroups could benefit from cholecalciferol supplemen-
tation. Further studies are warranted to evaluate this.
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